Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen. [PDF]
TBI-223, a novel oxazolidinone for tuberculosis, is designed to provide improved efficacy and safety compared to linezolid in combination with bedaquiline and pretomanid (BPaL).
Bigelow, Kristina +17 more
core +1 more source
Design, synthesis and anti-TB evaluation of 6 dialkylaminopyrimidine carboxamides [PDF]
, 2021 : Tuberculosis (TB) is an infectious airborne disease that is caused by Mycobacterium tuberculosis (Mtb). The World Health Organization (WHO) reported that TB was responsible for 1.4 million deaths worldwide in 2019. Most of these deaths occurred in poor
Tshinavhe, Ronewa
core +1 more source
Drug resistance of Mycobacterium tuberculosis to linezolid and delamanid: a case report from Bukavu, Democratic Republic of Congo [PDF]
The emergence of resistance is of great concern in the control of TB, especially to the new and repurposed drugs needed for the treatment of rifampicin resistance.
Bahizire, E +14 more
core +1 more source
Combating Multi-drug Resistant Mycobacterium Species by Efflux Pump Inhibitors: Contemporary Trends [PDF]
Tuberculosis (TB) is caused by Mycobacterium tuberculosis (M.tb) complex (MTBC), which includes M.tb as one of the causative bacteria. In contrast, non-tuberculous mycobacteria (NTM) refers to Mycobacterium spp. that do not cause TB or leprosy (MTBC spp.,
Amit Kadam +6 more
core +1 more source
Resistance to last-resort antibiotics in enterococci [PDF]
The genus Enterococcus comprises a diverse group of species, many of which are commensal members of the gut microbiota of humans and animals. The two most prominent species associated with humans, Enterococcus faecalis and Enterococcus faecium, have also
Allen, Freya +4 more
core +1 more source
Discovery of OJT008 as a Novel Inhibitor of Mycobacterium tuberculosis [PDF]
, 2022 Despite recent progress in the diagnosis of Tuberculosis (TB), the chemotherapeutic management of TB is still challenging. Mycobacterium tuberculosis (Mtb) is the etiological agent of TB, and TB is classified as the 13th leading cause of death globally ...
Onyenaka, Collins Chidi
core +1 more source
Fighting antimicrobial resistance in mycobacteria: development of an antivirulence screening platform and a genetic methodology to confirm drug resistance phenotypes [PDF]
, 2023 ¿RESUMENLa tuberculosis (TB) causó 10,6 millones de nuevos casos y 1,6 millones de muertes en 2021 según datos de la Organización Mundial de la Salud (OMS).
Calvet Seral, Juan +2 more
core
Tuberculosis farmacorresistente: Mecanismos moleculares de Mycobacterium tuberculosis [PDF]
In this traditional review, we describe factors from both Mycobacterium tuberculosis (M. tb) and the host that are associated for tuberculosis drug-resistant.
García-Maldonado, José Q. +4 more
core +2 more sources
Decoding the WHO Global Tuberculosis Report 2024: A Critical Analysis of Global and Chinese Key Data [PDF]
The World Health Organization (WHO) “Global Tuberculosis Report 2024” underscores the ongoing challenges and progress in the global fight against tuberculosis (TB). Despite a slowdown in the annual increase in TB cases and a decline in TB-related deaths,
Guirong Wang +18 more
core +1 more source
Investigating the molecular mode of action of new series of antituberculosis compounds and the role of the Tap efflux pump in persistence and drug tolerance in mycobacteria [PDF]
, 2023 La tuberculosis sigue siendo hoy en día una de las enfermedades infecciosas más mortales a nivel mundial. Por ello, es necesario desarrollar nuevos fármacos con mecanismos de acción novedosos que sean eficaces frente a cepas multirresistentes de ...
Aínsa Claver, José Antonio +2 more
core